Talphera, Inc. (NASDAQ:TLPH) Sees Large Increase in Short Interest

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 168,300 shares, an increase of 38.9% from the May 15th total of 121,200 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average daily volume of 63,700 shares, the short-interest ratio is presently 2.6 days.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TLPH shares. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Talphera in a report on Wednesday, May 15th. Maxim Group assumed coverage on Talphera in a report on Monday, May 6th. They set a “buy” rating and a $3.00 price objective on the stock.

Talphera Trading Up 8.2 %

TLPH stock opened at $1.06 on Friday. Talphera has a 52 week low of $0.43 and a 52 week high of $1.61. The business’s 50-day moving average is $1.04.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. On average, equities analysts predict that Talphera will post -0.84 earnings per share for the current year.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.